References
- Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, Reneman R S, Janssen P AJ. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective β1-adrenoceptor antagonist. J Cardiovascular Pharmacol 1988; 11: 552–563
- Janssens W J, Van de Water A, Xhonneux R, Reneman R S, van Nueten J M, Janssen P AJ. Nebivolol is devoid of intrinsic sympathomimetic activity. Eur J Pharmacol 1989; 159: 89–93
- Sieben G, Van Neuten L, Symoens J. Nebivolol dose-finding study in essential hypertension: a Belgian multicenter trial by general practitioners. Janssen Research Foundation. 1990, B-2340 Beerse, Belgium
- Esler M D, Julius S, Randall O S, Ellis C N, Kashima T. Relation of renin status to neurogenic vascular resistance in borderline hypertension. Am J Cardiol 1975; 36: 708–715
- Woods J R, Williams J G, Tavel M. The two-period crossover design in medical research. Ann Int Med 1989; 110: 560–566
- Vanhees L, Fagard R, Mespel P, et al. Renin release: β1- or β2-receptor mediated?. N Eng J Med 1985; 312: 123–124
- Van de Water A, Xhonneux R, Reneman R S, Janssen P AJ. Cardiovascular events of dl-nebivolol and its enantiomers, a comparison with those of atenolol. Eur J Pharmacol 1988; 156: 95–103
- Xhonneux R, Winters L, Reneman R S, Janssen P AJ. The 1-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer. Eur J Pharmacol 1990; 181: 261–265
- Loots W, De Clerk F. Differential effects of nebivolol on adrenoceptors in the heart and resistance arterioles in the rat. Quantitative intravital microscopic analysis. Eur J Pharmacol 1990; 179: 177–186
- Gao Y S, Nagao T, Bond R A, Janssen W J, Vanhoutte P M. Nevivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991; 17: 964–969